Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
20695746
DOI
10.1586/eri.10.63
Knihovny.cz E-resources
- MeSH
- Antiviral Agents therapeutic use MeSH
- Chemoprevention MeSH
- Cytomegalovirus Infections immunology prevention & control virology MeSH
- Cytomegalovirus drug effects MeSH
- Transplantation, Homologous adverse effects MeSH
- Humans MeSH
- Graft Rejection epidemiology immunology prevention & control virology MeSH
- Kidney Transplantation adverse effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Antiviral Agents MeSH
The adverse impact of cytomegalovirus (CMV) infection after solid organ transplantion is currently believed to be mediated primarily by its immunomodulatory effects. There is a large body of evidence showing that both CMV disease and asymptomatic viremia are independent risk factors for the development of allograft rejection. The aim of this article is to summarize mechanisms whereby CMV is involved in the development and progression of allograft rejection, with particular emphasis on renal transplant recipients. The article will also address the potential of anti-CMV preventive protocols designed to favorably affect the incidence of allograft rejection.
References provided by Crossref.org
